Antibodies that bind il-4 and/or il-13 and their uses

Abstract

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

1 : A humanized antibody that specifically binds to IL-4. 
     
     
         2 : The antibody of  claim 1  comprising a variable light chain domain consisting of SEQ ID NO: 3. 
     
     
         3 : The antibody of  claim 1  comprising a variable heavy chain domain selected from the group consisting of SEQ ID NO: 4 and SEQ ID NO: 5. 
     
     
         4 - 6 . (canceled) 
     
     
         7 : A nucleic acid encoding the antibody of  claim 1 . 
     
     
         8 . (canceled) 
     
     
         9 : A cell comprising a vector comprising the nucleic acid of  claim 7 . 
     
     
         10 : A humanized antibody that specifically binds to IL-13. 
     
     
         11 : The antibody of  claim 10  comprising a variable light chain domain consisting of SEQ ID NO: 1. 
     
     
         12 : The antibody of  claim 11  comprising a variable heavy chain domain consisting of SEQ ID NO: 2. 
     
     
         13 - 15 . (canceled) 
     
     
         16 : A nucleic acid encoding the antibody of  claim 10 . 
     
     
         17 . (canceled) 
     
     
         18 : A cell comprising a vector comprising the nucleic acid of  claim 16 . 
     
     
         19 : A bispecific antibody or bispecific antibody fragment that specifically binds to IL-13 and IL-4, wherein the bispecific antibody or bispecific antibody fragment comprises a light chain variable domain VL hB-B13 , a light chain variable domain VL hBD4-8 , a heavy chain variable domain VH hB-B13  and a heavy chain variable domain VH hBD4-8 ; wherein:
 VL hB-B13  comprises CDRs comprising the amino acid sequences RASESVDSYGQSYMH (SEQ ID NO: 8), LASNLES (SEQ ID NO: 9), and QQNAEDSRT (SEQ ID NO: 10);   VL hBD4-8  comprises CDRs comprising the amino acid sequences HASQNIDVWLS (SEQ ID NO: 14), KASNLHTG (SEQ ID NO: 15), and QQAHSYPFT (SEQ ID NO: 16),   VH hB-B13  comprises CDRs comprising the amino acid sequences GFSLTDSSIN (SEO ID NO: 11), DGRID (SEQ ID NO: 12), and DGYFPYAMDF (SEQ ID NO: 13),   VH hBD4-8  comprises CDRs comprising the amino acid sequences GYSFTSYWIH (SEQ ID NO: 17), IDPSDGETR (SEQ ID NO: 18) and LKEYGNYDSFYFDV (SEQ ID NO: 19) or the amino acid sequences GYSFTSYWIH (SEQ ID NO: 17), IDASDGETR (SEQ ID NO: 21), and LKEYGNYDSFYFDV (SEQ ID NO: 19).   
     
     
         20 - 28 . (canceled) 
     
     
         29 : A pharmaceutical composition comprising the humanized antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         30 . (canceled) 
     
     
         31 : The humanized antibody of  claim 1  that is further conjugated to an effector molecule. 
     
     
         32 - 34 . (canceled) 
     
     
         35 : A method of treating an allergic disease in a mammal comprising the step of administering to said mammal therapeutically effective amount of the bispecific antibody or antibody fragment according to  claim 19 . 
     
     
         36 . (canceled) 
     
     
         37 : A method of treating cancer comprising the step of administering to said mammal therapeutically effective amount of the bispecific antibody or antibody fragment according to  claim 19 . 
     
     
         38 - 44 . (canceled) 
     
     
         45 : A nucleic acid encoding the bispecific antibody of  claim 19 . 
     
     
         46 . (canceled) 
     
     
         47 : A cell comprising a vector comprising the nucleic acid of  claim 45 . 
     
     
         48 - 49 . (canceled)